GAME OF STROKE - by AZ Groeninge Every minute counts in a stroke, so it's important that children can also act quickly That is why az groeninge, with the help of Belgian Stroke Council, is...
Blog
BSC statement regarding the use of TNK for treatment of acute ischemic stroke
The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium....
Prevent, Treat and Support: a manifesto for stroke survivors
The Stroke Alliance for Stroke ( SAFE) and the European Stroke Organisation (ESO) have published a manifesto outlining a number of keypoints to improve prevention, treatment and support for stroke...
BSC Applauds Initial Step in Stroke Care Structuring but Calls for Uniform Criteria Across Regions
On 23 May 2024, the BSC published a press release applauding the recognition of Belgian S2 centres, but calling for uniform certification criteria across the country. Read it here
Remboursement Xarelto 2,5 mg
We are delighted to announce that neurologists also have been recognised for the reimbursement of Xarelto 2.5mg in coronary artery disease (CAD) and peripheral artery disease PAD), since February 1,...
2023 Symposium minutes
Symposium is closed... ... but it still time to check the summary, the short presentations the speakers made and to have a look at the pictures of the day !
Actilyse vials with latex plugs that could also contain traces of Gentamycine.
Dear members of the SB, As part of the strategy to resolve the worldwide shortage of thrombolytic therapy, the BSC has been informed that Boehringer-Ingelheim will temporarily produce Actilyse vials...
Joint Statement ESO and SAFE commemorate European Stroke Awareness Day 9 May 2023
Europe is failing to provide adequate stroke care and support The scale of stroke care crisis is laid bare by new data release New data collected as part of the Stroke Action Plan for Europe (SAP-E)...
Update on Alteplase and Tenecteplase shortage – ESO Statement and Information
On April 14, the ESO published their 4th information letter about alteplase and tenecteplase shortage in Europe.